This is to inform that, pursuant to Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation of our intimation dated 09th September, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Boston Bio Systems Limited (BSE: 531458) has resubmitted its Annual Report for FY 2023-24, citing improper formatting in the version originally filed on 9th September 2024. The financials reveal the company reported zero income during the year, with expenditure of Rs. 14.07 lacs widening the loss after tax from Rs. 0.22 lacs in FY23 to Rs. 14.07 lacs in FY24. The Directors' Responsibility Statement confirms accounts were prepared on a going concern basis. The board saw significant churn, with three new independent directors appointed and three directors (including a Managing Director) resigning between January and February 2024. No qualifications or adverse remarks were made by the statutory or secretarial auditors.
For shareholders, this is largely an administrative correction rather than a fundamental change, but the underlying results remain weak — zero revenue and a wider loss raise questions about the company's business activity. The revision itself is unlikely to move the stock, though the persistent lack of income is a red flag worth monitoring.